IL6 and diabetic kidney disease: Indirectly, this mechanism ameliorates obesity-related DKD by lowering systemic levels of inflammatory mediators such as TNF-α and IL-6, improving insulin sensitivity, and ultimately inhibiting glomerulosclerosis and fibrosis progression (138, 145).